METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to reverse fatty liver damage in phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called IBI362 in 165 adults with MASH, a serious fatty liver disease with liver scarring. Participants will receive either a low dose, high dose, or placebo for 60 weeks. The main goal is to see if the drug can resolve MASH without worsening …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 17, 2026 08:51 UTC
-
New drug shows promise for fatty liver disease in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called UBT251 for people with MASH, a serious liver condition linked to metabolism. About 156 adults with moderate to advanced liver scarring will receive either the drug or a placebo for 48 weeks. The goal is to see if the drug can reverse liver d…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 08:46 UTC
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis study tests a medicine called survodutide, given as a weekly injection, in 1800 adults with MASH (a fatty liver disease) and moderate to advanced liver scarring. The goal is to see if it can improve or reverse liver damage without worsening scarring. Participants are randoml…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug shows promise for fatty liver disease in early trial
Disease control Recruiting nowThis early-phase study tests whether the drug miricorilant can lower fat production in the liver for people with MASH, a common liver condition linked to metabolism. Eight participants will take the drug for 6 weeks, and researchers will measure changes in liver fat using scans a…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Gene silencer aims to halt liver scarring in MASH patients
Disease control Recruiting nowThis study tests an experimental drug called ALN-HSD for people with MASH, a liver disease caused by fat buildup that leads to scarring and possible liver failure. The drug uses gene silencing to target the root cause and reduce liver fibrosis. About 120 adults with genetic risk …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New pill could shrink fatty liver and help weight loss
Disease control Recruiting nowThis study tests an experimental medicine called CS060380, taken with a weight-loss drug (semaglutide), in adults with fatty liver disease (MASH) and obesity. About 120 people will join for up to 54 weeks. The goal is to see if the drug reduces liver fat and body weight safely.
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
What do MASH patients really think? new study asks before and after care
Knowledge-focused Recruiting nowThis study talks to 25 people with MASH (a liver condition) to learn what they expect, need, and understand about their disease. Participants are interviewed twice: once before and once after joining a special care program. The goal is to improve how doctors support patients, not…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC